Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of the Safety and Preliminary Efficacy of Intramedullary Spinal Cord Transplantation of Human Central Nervous System (CNS) Stem Cells (HuCNS-SC) in Subjects With Thoracic (T2-T11) Spinal Cord Trauma

Next Previous
X
Search
Trial Profile

A Phase I/II Study of the Safety and Preliminary Efficacy of Intramedullary Spinal Cord Transplantation of Human Central Nervous System (CNS) Stem Cells (HuCNS-SC) in Subjects With Thoracic (T2-T11) Spinal Cord Trauma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adult neural stem cells (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions
  • Sponsors StemCells

    • Most Recent Events

    • 09 Jul 2015 According to StemCells media release, data from this trial has been presented at the International Society for Stem Cell Research (ISSCR) 2015 Annual Meeting.
    • 17 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 May 2015 Results were presented in StemCells media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top